Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epratuzumab I-131

Drug Profile

Epratuzumab I-131

Alternative Names: Anti-CD22 monoclonal antibody LL2-I-131; IMMU LL2-I-131; ImmuRAIT-LL2-I -131; LymphoCide I -131; Monoclonal antibody LL2-I-131

Latest Information Update: 11 Oct 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunomedics
  • Developer Immunomedics; Repligen Corporation
  • Class Monoclonal antibodies
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 08 Aug 2001 US patent issued to Immunomedics covering the engineering of a glycosylation site on anti-CD22 antibodies for the purpose of attaching drugs or isotopes without affecting targeting
  • 24 Feb 2000 A phase I study in non-Hodgkin's lymphoma has been added to the therapeutic trials section
  • 01 Oct 1997 Immunomedics has licensed production technology for LymphocideTM from Repligen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top